Topoisomerase II and the response to antileukemic therapy.
A number of recent studies have investigated the expression of topoisomerase II in clinical leukemia specimens. Here we outline the rationale for these studies, identify potential pitfalls, summarize recent results, and discuss unanswered questions in this area.
Kaufmann
S H
SH
Division of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA. Kaufmann.Scott@Mayo.edu
Gore
S D
SD
Miller
C B
CB
Jones
R J
RJ
Zwelling
L A
LA
Schneider
E
E
Burke
P J
PJ
Karp
J E
JE
D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D002648:Child; D004249:DNA Damage; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000502:physiology; D004273:DNA, Neoplasm / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D012333:RNA, Messenger / Q000032:analysis; D059005:Topoisomerase II Inhibitors
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D012333:RNA, Messenger; D059005:Topoisomerase II Inhibitors; D004250:DNA Topoisomerases, Type II